Health Care Utilization and Costs of Patients With Prostate Cancer in China Based on National Health Insurance Database From 2015 to 2017.
China
burden of disease
direct medical costs
health care utilization
prostate cancer
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
20
01
2020
accepted:
30
04
2020
entrez:
27
6
2020
pubmed:
27
6
2020
medline:
27
6
2020
Statut:
epublish
Résumé
In terms of medical costs, prostate cancer is on the increase as one of the most costly cancers, posing a tremendous economic burden, but evidence on the health care utilization and medical expenditure of prostate cancer has been absent in China. This study aimed to analyze health care utilization and direct medical costs of patients with prostate cancer in China. Health care service data with a national representative sample of basic medical insurance beneficiaries between 2015 and 2017 were obtained from the China Health Insurance Association database. We conducted descriptive and statistical analyses of health care utilization, annual direct medical costs, and composition based on cancer-related medical records. Health care utilization was measured by the number of hospital visits and the length of stay. A total of 3,936 patients with prostate cancer and 24,686 cancer-related visits between 2015 and 2017 were identified in the database. The number of annual outpatient and inpatient visits per patient differed significantly from 2015 to 2017. There was no obvious change in length of stay and annual direct medical costs from 2015 to 2017. The number of annual visits per patient (outpatient: 3.0 vs. 4.0, P < 0.01; inpatient: 1.5 vs. 2.0, P < 0.001) and the annual medical direct costs per patient (US$2,300.1 vs. US$3,543.3, P < 0.001) of patients covered by the Urban Rural Resident Basic Medical Insurance (URRBMI) were both lower than those of patients covered by the Urban Employee Basic Medical Insurance (UEBMI), and the median out-of-pocket expense of URRBMI was higher than that of UEBMI (US$926.6 vs. US$594.0, P < 0.001). The annual direct medical costs of patients with prostate cancer in Western regions were significantly lower than those of patients in Eastern and Central regions (East: US$4011.9; Central: US$3458.6; West: US$2115.5) (P < 0.001). There was an imbalanced distribution of health care utilization among regions in China. The direct medical costs of Chinese patients with prostate cancer remained stable, but the gap in health care utilization and medical costs between two different insurance schemes and among regions still needed to be further addressed.
Sections du résumé
BACKGROUND
BACKGROUND
In terms of medical costs, prostate cancer is on the increase as one of the most costly cancers, posing a tremendous economic burden, but evidence on the health care utilization and medical expenditure of prostate cancer has been absent in China.
OBJECTIVE
OBJECTIVE
This study aimed to analyze health care utilization and direct medical costs of patients with prostate cancer in China.
METHODS
METHODS
Health care service data with a national representative sample of basic medical insurance beneficiaries between 2015 and 2017 were obtained from the China Health Insurance Association database. We conducted descriptive and statistical analyses of health care utilization, annual direct medical costs, and composition based on cancer-related medical records. Health care utilization was measured by the number of hospital visits and the length of stay.
RESULTS
RESULTS
A total of 3,936 patients with prostate cancer and 24,686 cancer-related visits between 2015 and 2017 were identified in the database. The number of annual outpatient and inpatient visits per patient differed significantly from 2015 to 2017. There was no obvious change in length of stay and annual direct medical costs from 2015 to 2017. The number of annual visits per patient (outpatient: 3.0 vs. 4.0, P < 0.01; inpatient: 1.5 vs. 2.0, P < 0.001) and the annual medical direct costs per patient (US$2,300.1 vs. US$3,543.3, P < 0.001) of patients covered by the Urban Rural Resident Basic Medical Insurance (URRBMI) were both lower than those of patients covered by the Urban Employee Basic Medical Insurance (UEBMI), and the median out-of-pocket expense of URRBMI was higher than that of UEBMI (US$926.6 vs. US$594.0, P < 0.001). The annual direct medical costs of patients with prostate cancer in Western regions were significantly lower than those of patients in Eastern and Central regions (East: US$4011.9; Central: US$3458.6; West: US$2115.5) (P < 0.001).
CONCLUSIONS
CONCLUSIONS
There was an imbalanced distribution of health care utilization among regions in China. The direct medical costs of Chinese patients with prostate cancer remained stable, but the gap in health care utilization and medical costs between two different insurance schemes and among regions still needed to be further addressed.
Identifiants
pubmed: 32587512
doi: 10.3389/fphar.2020.00719
pmc: PMC7299164
doi:
Types de publication
Journal Article
Langues
eng
Pagination
719Informations de copyright
Copyright © 2020 Bai, Wushouer, Huang, Luo, Guan and Shi.
Références
BMC Urol. 2019 Mar 18;19(1):19
pubmed: 30885200
Aust Health Rev. 2018 Feb;42(1):39-44
pubmed: 28263706
CMAJ. 2000 Apr 4;162(7):987-92
pubmed: 10763396
Annu Rev Public Health. 2017 Mar 20;38:431-448
pubmed: 28125384
Asian Pac J Cancer Prev. 2018 Jan 27;19(1):21-26
pubmed: 29373875
Zhonghua Zhong Liu Za Zhi. 2019 Jan 23;41(1):19-28
pubmed: 30678413
Asia Pac J Clin Oncol. 2017 Jun;13(3):152-159
pubmed: 28303657
Prostate Cancer Prostatic Dis. 2010 Jun;13(2):162-7
pubmed: 20125121
Lancet. 2016 Jan 16;387(10015):251-72
pubmed: 26510778
Curr Oncol. 2013 Dec;20(6):e522-31
pubmed: 24311952
Chin J Cancer Res. 2016 Apr;28(2):168-79
pubmed: 27199514
Pak J Med Sci. 2013 May;29(3):793-8
pubmed: 24353630
Int J Equity Health. 2017 Mar 3;16(1):42
pubmed: 28253876
Medicine (Baltimore). 2019 Aug;98(33):e16718
pubmed: 31415365
BMC Health Serv Res. 2015 Oct 05;15:453
pubmed: 26438194
BJU Int. 2010 Jan;105(1):49-56
pubmed: 20132102
CMAJ. 1999 Mar 9;160(5):685-90
pubmed: 10102004
Bull World Health Organ. 2014 Jan 1;92(1):29-41
pubmed: 24391298
Lancet. 2015 Oct 10;386(10002):1484-92
pubmed: 26466052
Value Health. 2011 Jun;14(4):499-505
pubmed: 21669375
PLoS One. 2015 Dec 17;10(12):e0144809
pubmed: 26679187
Cancer Manag Res. 2017 Dec 07;9:789-800
pubmed: 29263702
J Med Econ. 2010;13(2):351-61
pubmed: 20491610
J Med Econ. 2017 May;20(5):549-553
pubmed: 28286996
J Natl Cancer Inst. 2011 Jan 19;103(2):117-28
pubmed: 21228314
BMJ. 2019 Jun 21;365:l2378
pubmed: 31227485
BMJ Open. 2019 Nov 28;9(11):e031658
pubmed: 31784440
BMJ. 2019 Jun 21;365:l2369
pubmed: 31227508
J Urol. 2004 Jun;171(6 Pt 1):2250-4
pubmed: 15126796
Clin Epidemiol. 2019 Dec 10;11:1057-1065
pubmed: 31849536
Eur Urol. 2020 Jan;77(1):38-52
pubmed: 31493960
Cancer. 2017 Sep 15;123(18):3591-3601
pubmed: 28542732
J Health Econ. 2002 Jan;21(1):147-59
pubmed: 11852912
Lancet. 2016 Mar 26;387(10025):1274-5
pubmed: 27025430
J Med Econ. 2019 Aug;22(8):728-735
pubmed: 30913930
Cancer. 2007 Feb 1;109(3):518-27
pubmed: 17186528
J Geriatr Cardiol. 2015 Sep;12(5):502-6
pubmed: 26512241
BJU Int. 2010 Feb;105(3):338-46
pubmed: 19594734
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Scand J Urol Nephrol. 2003;37(5):371-5
pubmed: 14594683
Health Econ. 2014 Mar;23(3):314-31
pubmed: 23794362
BMJ Open. 2019 Jun 22;9(6):e028214
pubmed: 31230019
Health Econ. 2017 Jul;26(7):853-862
pubmed: 27683015
BMJ. 2019 Jun 19;365:l2349
pubmed: 31217222
Lancet Oncol. 2013 Nov;14(12):1165-74
pubmed: 24131614